Barclays Cuts 10x Genomics (NASDAQ:TXG) Price Target to $18.00

10x Genomics (NASDAQ:TXG) had its price target reduced by Barclays from $19.00 to $18.00 in a research report released on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages also recently commented on TXG. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, February 1st. Citigroup dropped their price objective on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. The Goldman Sachs Group dropped their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. UBS Group dropped their price objective on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. dropped their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, 10x Genomics presently has an average rating of “Moderate Buy” and a consensus price target of $23.79.

10x Genomics Trading Up 1.5 %

NASDAQ TXG opened at $12.00 on Monday. The stock’s 50 day moving average is $14.82 and its two-hundred day moving average is $17.47. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -7.84 and a beta of 1.85. 10x Genomics has a 1-year low of $11.55 and a 1-year high of $51.22.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. On average, analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.

Institutional Trading of 10x Genomics

A number of large investors have recently made changes to their positions in TXG. KBC Group NV boosted its stake in 10x Genomics by 38.8% in the 3rd quarter. KBC Group NV now owns 3,225 shares of the company’s stock worth $73,000 after purchasing an additional 902 shares during the period. Atria Wealth Solutions Inc. boosted its stake in 10x Genomics by 9.6% in the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company’s stock worth $155,000 after purchasing an additional 943 shares during the period. First Horizon Advisors Inc. boosted its stake in 10x Genomics by 53.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after purchasing an additional 1,012 shares during the period. Blue Trust Inc. boosted its stake in 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after purchasing an additional 1,025 shares during the period. Finally, GAMMA Investing LLC boosted its stake in 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after purchasing an additional 1,265 shares during the period. Institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.